P/E ratio for Biotest (BIO.F)
P/E ratio as of April 2025 (TTM): -168
According to Biotest 's latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is -167.633. At the end of 2022 the company had a P/E ratio of -51.6.
P/E ratio history for Biotest from 2009 to 2023
PE ratio at the end of each year
| Year | P/E ratio | Change |
|---|---|---|
| 2022 | -51.6 | 97.02% |
| 2021 | -26.2 | -25.48% |
| 2020 | -35.1 | -72.49% |
| 2019 | -128 | -2375.15% |
| 2018 | 5.61 | -102.73% |
| 2017 | -205 | 1385.86% |
| 2016 | -13.8 | 57.93% |
| 2015 | -8.76 | -114.33% |
| 2014 | 61.1 | 99.51% |
| 2013 | 30.6 | 65.68% |
| 2012 | 18.5 | 77.59% |
| 2011 | 10.4 | -33.03% |
| 2010 | 15.5 | -13.68% |
| 2009 | 18.0 |
How to read a P/E ratio?
The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share. A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.
Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.